After speaking with Teva's head IP counsel, RBC Capital analyst Randall Stanicky believes that the chances of a generic version of the company's Copaxone drug being launched early next year "look increasingly less likely." The analyst expects a decision from a trial on the matter to be handed down in the first quarter of 2017. He says that if Teva's claim on one of four patents is upheld in the trial, an injunction against generic Copaxone would be issued that would be valid until 2H18. If Teva wins an appeal against such a decision, generic Copaxone would be delayed until 2030, Stanicky stated. He expects litigation on additional patents to continue for several years, and he believes that the stock's risk/reward ratio is positive, given low investor expectations. The analyst keeps a $71 price target and Outperform rating on the stock.